周三，花旗开始对吉利德科学公司(NASDAQ:GILD)进行覆盖，给予该股买入评级，并将目标价设定为125美元。这一积极展望基于多个因素，包括公司HIV治疗药物Biktarvy的预期增长，以及即将推出的药物lenacapavir的潜力。

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

中国食品药品网讯（记者落楠） 11月10日，第七届中国国际进口博览会（以下简称进博会）在上海落下帷幕。进博会药品板块集中布局7.2馆，汇聚十余家世界500强制药企业，今年企业带来的展品有哪些新看点？

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

Major purchases of the most advanced medical equipment and consumables, and cooperation on major infectious diseases such as ...

本次进博会现场，吉利德与中国癌症基金会签订了一项为期三年的战略合作备忘录，以提高晚期乳腺癌患者生存期与生活质量为核心目标，在优化诊疗路径、提升创新药物可及性、科研临床协同发展、用药不良反应监测、癌症监测管理体系等关键维度发力，形成全方位、多层次的癌症防治合力。此外，吉利德科学支持的“创新引领 ...

以艾滋病为例，尽管随着药物创新和诊疗水平的不断提升，艾滋病已经成为可防可治的慢性疾病，但艾滋病仍是我国导致死亡人数最高的传染病。HIV感染者晚发现比例仍然较高、青年人群感染病例还在持续增加、地区防控水平存在明显差异、并发症问题严峻、社会对艾滋病的污名 ...